King Wealth Management Group Sells 25,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

King Wealth Management Group decreased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,000 shares of the company’s stock after selling 25,000 shares during the period. King Wealth Management Group’s holdings in Teva Pharmaceutical Industries were worth $4,213,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Global Retirement Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the last quarter. Banque Cantonale Vaudoise grew its holdings in shares of Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after purchasing an additional 306 shares during the last quarter. Ethic Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after purchasing an additional 325 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TEVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This represents a 34.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the transaction, the executive vice president owned 57,478 shares in the company, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 1,280,269 shares of company stock worth $42,755,980 over the last quarter. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 1.7%

Shares of Teva Pharmaceutical Industries stock opened at $34.66 on Wednesday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries Ltd. has a 1 year low of $14.99 and a 1 year high of $37.35. The firm’s 50-day moving average is $32.05 and its two-hundred day moving average is $31.16. The stock has a market cap of $39.85 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 3.29 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion for the quarter. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.